Omnicell (FRA:OC9) Beneish M-Score: -2.74 (As of Jul. 09, 2026)


FRA:OC9 Omnicell Inc FRA:OC9
76 GF Score
Price €38.80
GF Value €33.35
! 6 Warning Signs
View Full Analysis

What is Omnicell Beneish M-Score?

Omnicell FRA:OC9 76 Beneish M-Score is -2.74 as of Jul. 09, 2026. GuruFocus rates FRA:OC9 with a GF Score™ of 76/100 and a GF Value™ of €33.35. The stock has 6 warning signs investors should review. Among 631 Healthcare Providers & Services companies, Omnicell ranks better than 63.07% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.74 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Omnicell's Beneish M-Score or its related term are showing as below:

FRA:OC9' s Beneish M-Score Range Over the Past 10 Years
Min: -3.34   Med: -2.69   Max: -1.95
Current: -2.74

During the past 13 years, the highest Beneish M-Score of Omnicell was -1.95. The lowest was -3.34. And the median was -2.69.


Omnicell Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Omnicell's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omnicell Beneish M-Score Chart

Omnicell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.53 -2.46 -3.01 -2.75 -2.85

Omnicell Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.69 -2.72 -2.69 -2.85 -2.74

FRA:OC9 vs TDOC, SDGR, OMDA: Beneish M-Score Comparison

For the Health Information Services subindustry, Omnicell's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Omnicell Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Omnicell's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Omnicell's Beneish M-Score falls into.


FRA:OC9
76GF Score
Omnicell Inc FRA:OC9
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Omnicell Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Omnicell for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9296+0.528 * 0.9908+0.404 * 1.0465+0.892 * 0.9987+0.115 * 1.026
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.974+4.679 * -0.067248-0.327 * 0.8958
=-2.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was €216 Mil.
Revenue was 268.046 + 268.142 + 264.658 + 251.917 = €1,053 Mil.
Gross Profit was 121.414 + 111.298 + 114.597 + 110.697 = €458 Mil.
Total Current Assets was €625 Mil.
Total Assets was €1,734 Mil.
Property, Plant and Equipment(Net PPE) was €125 Mil.
Depreciation, Depletion and Amortization(DDA) was €73 Mil.
Selling, General, & Admin. Expense(SGA) was €352 Mil.
Total Current Liabilities was €418 Mil.
Long-Term Debt & Capital Lease Obligation was €165 Mil.
Net Income was 9.825 + -1.73 + 4.654 + 4.889 = €18 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = €0 Mil.
Cash Flow from Operations was 47.142 + 25.922 + 24.083 + 37.069 = €134 Mil.
Total Receivables was €233 Mil.
Revenue was 249.443 + 293.069 + 254.46 + 257.136 = €1,054 Mil.
Gross Profit was 102.616 + 135.382 + 110.163 + 106.232 = €454 Mil.
Total Current Assets was €777 Mil.
Total Assets was €1,990 Mil.
Property, Plant and Equipment(Net PPE) was €134 Mil.
Depreciation, Depletion and Amortization(DDA) was €82 Mil.
Selling, General, & Admin. Expense(SGA) was €362 Mil.
Total Current Liabilities was €562 Mil.
Long-Term Debt & Capital Lease Obligation was €185 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(216.074 / 1052.763) / (232.727 / 1054.108)
=0.205245 / 0.220781
=0.9296

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(454.393 / 1054.108) / (458.006 / 1052.763)
=0.431069 / 0.435051
=0.9908

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (624.792 + 124.953) / 1733.553) / (1 - (776.692 + 134.199) / 1990.11)
=0.56751 / 0.542291
=1.0465

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=1052.763 / 1054.108
=0.9987

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(82.023 / (82.023 + 134.199)) / (73.304 / (73.304 + 124.953))
=0.379346 / 0.369742
=1.026

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(351.965 / 1052.763) / (361.82 / 1054.108)
=0.334325 / 0.343248
=0.974

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((164.833 + 417.837) / 1733.553) / ((184.741 + 561.967) / 1990.11)
=0.336113 / 0.375209
=0.8958

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(17.638 - 0 - 134.216) / 1733.553
=-0.067248

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Omnicell has a M-score of -2.81 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.74 mean?
Omnicell (FRA:OC9) has a Beneish M-Score of -2.74 as of Jul. 09, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Omnicell and its competitors. According to the industry distribution chart, Omnicell ranks #233 out of 631 companies in the Healthcare Providers & Services industry, placing it in the top 36.9%.
Is Omnicell's Beneish M-Score too high?
Omnicell's current Beneish M-Score is -2.74. Based on the distribution chart, Omnicell ranks #233 out of 631 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Omnicell has a GF Score™ of 76/100, reflecting its overall financial health beyond just this single metric.
How does Omnicell's Beneish M-Score compare to TDOC and SDGR?
According to the Healthcare Providers & Services industry distribution chart, Omnicell ranks #233 out of 631 companies for Beneish M-Score. This puts Omnicell in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Omnicell and its competitors. Omnicell's current Beneish M-Score is -2.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Omnicell stock overvalued right now?
Omnicell (FRA:OC9) has a current Beneish M-Score of -2.74. The stock's GF Value™ is €33.35, compared to a current price of €38.80 — trading 16.3% above its estimated fair value. The current Beneish M-Score is -2.74. Omnicell's overall GF Score™ is 76/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Omnicell (FRA:OC9), the current Beneish M-Score is -2.74 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Omnicell (FRA:OC9) Overvalued in 2026?

Based on GuruFocus' analysis, Omnicell stock appears to be overvalued. The current stock price of €38.80 is trading 16.3% above its estimated GF Value™ of €33.35.

Key valuation signals for FRA:OC9:

  • Beneish M-Score: -2.74
  • GF Value™: €33.35 vs. price of €38.80 (16.3% above fair value)
  • GF Score™: 76/100 with 6 warning signs

No single metric tells the full story. See the FRA:OC9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Omnicell Business Description

Other Exchanges OMCL:USAOMCL:Mexico
Address 4220 North Freeway, Fort Worth, TX, USA, 76137
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
76GF Score

Get the complete analysis for FRA:OC9

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€38.80
Price
€33.35
GF Value